Xspray Pharma: NDA resubmission anticipated in Q4 - Redeye
Redeye provides a brief comment on Xspray following yesterday's confirmation of the anticipated Q4 2024 NDA resubmission for Dasynoc. The updated timeline aligns with our estimates, resulting in no changes to our forecasts or valuation.
ANNONS
Redeye provides a brief comment on Xspray following yesterday's confirmation of the anticipated Q4 2024 NDA resubmission for Dasynoc. The updated timeline aligns with our estimates, resulting in no changes to our forecasts or valuation.